Department of Urology, University of Iowa, Iowa City, IA 52242-1089, USA.
J Pediatr Urol. 2012 Jun;8(3):e27-30. doi: 10.1016/j.jpurol.2011.12.006. Epub 2011 Dec 29.
Endoscopic management of vesicoureteral reflux with dextranomer/hyaluronic copolymer (Deflux(®), Oceana Therapeutics, Inc., Edison, NJ, USA) has gained widespread acceptance with increasing success rates and minimal morbidity. Formation of a pseudocapsule and calcification are known histologic changes at the injection site. Postoperative ureteral obstruction has been reported in cases of severe voiding dysfunction, neurogenic bladder and abnormal ureteral anatomy. We present a case of chronic asymptomatic obstruction in a normal ureter following injection of 0.7 ml Deflux.
用葡聚糖/透明质酸共聚物（Deflux(®)，Oceana Therapeutics，Inc.，Edison，NJ，USA）进行内镜下处理膀胱输尿管反流已被广泛接受，其成功率不断提高，且发病率极低。在注射部位，形成假包膜和钙化是已知的组织学变化。在严重排尿功能障碍、神经性膀胱和异常输尿管解剖的情况下，有报道称术后输尿管梗阻。我们报告了一例在正常输尿管内注射 0.7ml Deflux 后发生慢性无症状梗阻的病例。
